fulvestrant / Generic mfg. - LARVOL DELTA

VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for HER-2 Negative and Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): Overall Survival Results of the CCTG/BCT MA.40/FINER Study (NCT04650581) (ESMO 2026) - P3 | No abstract available

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Estrogen-related mechanisms underlying bisphenol A-Induced proliferation and migration in MCF-7 breast cancer cells: An integrated network toxicology, molecular docking, and in vitro study. (PubMed, Ecotoxicol Environ Saf) - "The results showed that BPA promoted MCF-7 cell proliferation by activating the ESR1 signaling pathway and upregulated the expression of the downstream key protein Cyclin D1; this effect was abolished by the estrogen receptor antagonist Fulvestrant. In addition, BPA significantly enhanced cell migratory capacity, accompanied by increased EPHA2 expression and alterations in epithelial-mesenchymal transition markers, including increased vimentin expression and decreased E-cadherin expression. Collectively, these findings provide important evidence for understanding the multi-mechanistic pro-proliferative and pro-migratory effects through which BPA may act in estrogen-related tumors, offer new insights into its toxicological mechanisms, and contribute to a better understanding of the molecular basis underlying the potential hazards of BPA exposure."

Journal • Preclinical • Breast Cancer • Endometrial Cancer • Hormone Receptor Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CCNA2 • CCND1 • CDH1 • CDK1 • CDK2 • EPHA2 • VIM

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer (clinicaltrials.gov) - P3 | N=184 | Active, not recruiting | Sponsor: Fudan University | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

ctDNA and Thymidine Kinase Activity Identify High-Risk Disease and Resistance Evolution in HR+/HER2− Metastatic Breast Cancer: Data from the Fulvestrant±Palbociclib Randomized Phase II FLIPPER Trial (ESMO 2026) - No abstract available

Circulating tumor DNA • Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Evexomostat combined with capivasertib and fulvestrant in PI3K/AKT pathway-altered HR+/HER2– metastatic breast cancer: interim metabolic biomarker findings from the AMELIA-1 trial (ESMO 2026) - No abstract available

Biomarker • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Breast Cancer • Oncology • Solid Tumor

Transcriptional and functional consequences of epidermal growth factor receptor (EGFR) overexpression in fulvestrant-resistant breast cancer cell line models (ESMO 2026) - No abstract available

Preclinical • Breast Cancer • Oncology • Solid Tumor • EGFR

Final long-term outcomes of palbociclib-fulvestrant vs. placebo-fulvestrant in HR+/HER2‒ endocrine-sensitive advanced breast cancer: GEICAM/2014-12 (FLIPPER) phase II trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: a multicentre real-world study (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA • PTEN

Capivasertib + fulvestrant for patients (pts) with hormone receptor-positive (HR+) advanced breast cancer (ABC): Management of common adverse events (AEs) from the Phase III CAPItello-291 trial (ESMO 2026) - No abstract available

Adverse events • Clinical • Metastases • P3 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A observational study for safety and efficacy of Fulvestrant 500mg in postmenopausal patients with ER positive advanced or recurrent breast cancer after prior endocrine treatment. (SBCCSG-29) (clinicaltrials.gov) - P2 | N=100 | Enrolling by invitation | Sponsor: Saitama Breast Cancer Clinical Study Group(SBCCSG) | Unknown status ➔ Enrolling by invitation

Enrollment open • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER

A Bleeding Ulcer That Wasn't: Gastric Metastasis From Invasive Ductal Breast Carcinoma (ACG 2026) - "Her oncologic course was marked by axillary nodal recurrence in 2017, followed by progressive metastatic disease involving lung, bone, liver, and brain, treated with anastrozole, letrozole, fulvestrant/everolimus, alpelisib, trastuzumab deruxtecan, and elacestrant. Gastroenterologists evaluating GI bleeding in patients with breast cancer history should pursue targeted biopsy with breast-directed immunohistochemistry, as accurate classification carries direct therapeutic implications. Figure: Endoscopic findings showing a 2.5 cm ulcer on the greater curvature of the proximal body and multiple additional ulcers up to 1.5 cm along the antrum, distal body, and proximal body of the stomach."

Breast Cancer • Gastric Cancer • Gastrointestinal Disorder • HER2 Positive Breast Cancer • Oncology • Peptic Ulcer • Solid Tumor • CDH1 • GATA3 • PGR

The Great Masquerader: Metastatic Breast Cancer Presenting as Decompensated Cirrhosis (ACG 2026) - "She had been receiving anastrozole and was transitioned to fulvestrant. During fulvestrant monotherapy, she developed skull metastases, prompting addition of abemaciclib...Clinicians should consider GI metastases in patients with prior breast cancer who present with new nonspecific GI symptoms, including evidence of new cirrhosis. Early recognition and management are critical for improved outcomes."

Metastases • Acute Kidney Injury • Breast Cancer • CNS Disorders • Colonic Polyps • Colorectal Cancer • Endocrine Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Metabolic Disorders • Nephrology • Oncology • Peritoneal Cancer • Portal Hypertension • Renal Disease • Solid Tumor • GATA3 • GCDFP-15 • HER-2 • Mammaglobin • PGR

Supraphysiological Testosterone Differentially Regulates Aortic Atheroma and Cardiac Remodelling in the Testicular Feminised Mouse. (PubMed, Cells) - "Male Tfm mice and AR-intact XY littermate controls were fed a cholesterol-enriched diet for 28 weeks and received fortnightly intramuscular injections of saline or supraphysiological testosterone, alone or in combination with fulvestrant (oestrogen receptor antagonist) or anastrozole (aromatase inhibitor). In contrast, supraphysiological testosterone increased heart weight, cardiomyocyte size and expression of hypertrophic markers exclusively in XY mice, with no evidence of cardiac remodelling in Tfm mice. Collectively, these findings demonstrate divergent tissue-specific cardiovascular actions of testosterone, whereby supraphysiological exposure promotes AR-dependent cardiac remodelling without conferring additional vascular benefit, supporting maintenance of physiological testosterone concentrations during TTh."

Journal • Preclinical • Atherosclerosis • Cardiovascular

First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam. (PubMed, Front Oncol) - "We conducted a retrospective cohort study enrolling 107 patients who received first-line ribociclib or palbociclib in combination with an aromatase inhibitor or fulvestrant at Ho Chi Minh City Oncology Hospital between March 1, 2021, and April 1, 2023. Treatment outcomes and safety profiles were consistent with those reported in pivotal clinical trials and real-world studies. These findings should be interpreted in light of the retrospective single-center design, modest sample size, non-randomized treatment allocation, and immature OS data."

Journal • Real-world evidence • Breast Cancer • Febrile Neutropenia • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • HER-2

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region: A Retrospective Study (TREASURE Study). (PubMed, Int J Breast Cancer) - P | "Treatment regimens included palbociclib plus aromatase inhibitors (n = 142, 55.0%) and palbociclib with fulvestrant (n = 120, 46.5%). Larger studies with more patients are needed to further assess long-term clinical outcomes in this population. Trial Registration: ClinicalTrials.gov identifier: NCT04916509."

Clinical • Clinical data • Journal • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Identification and validation of the ESR1 Y537S mutant-enriched enhancer and its downstream target IGFBP3. (PubMed, Cancer Res Commun) - "Deletion of this enhancer region reduced cell proliferation and adhesion in vitro, decreased tumorigenicity in vivo, and enhanced sensitivity to fulvestrant specifically in cells harboring Y537S ER mutation. We subsequently identified IGFBP3 as a functional downstream target of this enhancer and validated its contribution to a subset of the phenotypes associated with Y537S mutant ER."

Journal • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • IGFBP3

Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial (SABCS 2025) - "Background: At the primary progression-free survival (PFS) analysis, the phase 3 EMBER-3 trial in patients (pts) with ER+, HER2- ABC demonstrated significant PFS benefit with imlunestrant (imlu) vs standard therapy (SOC: fulvestrant or exemestane) in pts with ESR1 mutations (ESR1m), and with imlunestrant+abemaciclib (imlu+abema) vs imlu in all pts, regardless of ESR1m status. At a median follow-up of 28.5 months, a clinically meaningful improvement in OS was observed with imlu vs SOC in pts with ESR1m (corresponding to a numeric increase in mOS of 11.4 months), however, the boundary for significance was not achieved. Also, a favorable OS trend emerged with imlu+abema vs imlu in all pts, regardless of ESR1m. Sustained benefit in PFS, with clinically meaningful improvement in TTC, and PFS2 further highlight the efficacy of imlu-based regimens."

Clinical • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58. (ASCO 2023) - P3 | "HER2-E cohort will randomized pts 1:1 to RIB+ET (letrozole or fulvestrant) or PAL+ET. As per recent protocol amendment, BL cohort pts will be treated with paclitaxel plus tislelizumab, an anti PD-1 monoclonal antibody, pts may be offered to try RIB + ET first, and will remain eligible for paclitaxel + tislelizumab upon progression...HARMONIA will recruit in Spain (55 sites), Portugal (5), and US (35) within SOLTI & AFT network. Clinical trial information: NCT05207709."

Clinical • Head-to-Head • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC) (SABCS 2023) - P2 | " Eligible pts had HER2+ (by local HER2 testing) and HR+, unresectable, locally advanced or mBC; ECOG PS ≤1; prior treatment with at least trastuzumab, pertuzumab, and T-DM1; and no prior CDK4/6 inhibitor...In the metastatic setting, pts received a median (range) of 4 (1-12) prior systemic regimens, 3 (1-10) prior different HER2-targeted therapies, and 1 (0-5) prior endocrine therapy; 12 (24%) pts had prior T-DXd and 11 (22%) had prior fulv... Zani + palbo + fulv showed a promising PFS6 and mPFS with durable responses. The safety profile was manageable. These results support further development of a novel chemotherapy-free treatment regimen for heavily pretreated pts with HER2+/HR+ mBC."

Late-breaking abstract • Metastases • P2a data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. (PubMed, Lancet Oncol) - P2 | "Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen."

Journal • P2a data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • HER-2